Sport Psychology

ued until the trial’s conclusion on day 45.

“Postpartum depression is underrecognized, undertreated and disruptive for those who live with the condition. We collaborate with researchers around the world in an effort to develop more rapid and effective therapies for the many women who need support,” said Deligiannidis in a press release from July after reaching phase 3 in clinical trials.

Results found that 57% of the women administered zuranolone showed a notable improvement of 50% or more in their depressive symptoms by day 15, as opposed to 38% of those who were given a placebo. At day 45, 61.9% of participants receiving zuranolone experienced a 50% or more improvement for their depressive symptoms compared to the 54.1% of women receiving a placebo.

stitutes, Karches Family Distinguished Chair in Medical Research. “The FDA approval stemming from her work will make available new therapeutic options that are clearly needed.” of the SKYLARK Study’s phase 3 clinical trials assessing zuranolone, findings were published with Deligiannidis as lead author in The American Journal of Psychiatry on July 26.

According to a recent study by the Centers for Disease Control and Prevention, the rate of diagnosing depression at the time of delivery was found to be sevenfold higher in 2015 than in 2000.

The Feinstein Institutes and Deligiannidis have received more than $4 million in multi-year grants to use non-invasive brain imaging to study how perinatal depression develops in women and to develop novel treatments, including bright light therapy, sleep modification and non-invasive vagus nerve stimulation to treat major depressive disorders.

The results showed significant relief after three days of treatment, merely after two doses, and this progress contin-

The most prevalent treatmentrelated side effects, observed in over 5% of participants in the zuranolone 50 mg group, were drowsiness, dizziness, sedation, headache, diarrhea, nausea, urinary tract infection, and Covid-19.

“Dr. Deligiannidis is a leader in clinical trials for postpartum depression, a condition that affects millions,” said Dr. Kevin J. Tracey, president and CEO of the Feinstein In-

Back in 2019, the FDA granted approval to brexanolone, marking it as the inaugural drug exclusively designated for postpartum depression treatment. This product, produced by Sage Therapeutics and marketed as Zulresso, has seen limited use because it costs $34,000 per dose and requires infusion lasting 60 hours within a hospital setting.

Sage Therapeutics and Biogen Inc. are also producing zuranoloneso, but so far do not have a price for the postpartum depression pill.

Dr. Tom Ferraro has specialized in sport psychology for 20 years and works in the fields of golf, tennis, soccer, baseball, football, wrestling, lacrosse, figure skating, gymnastics, softball, fencing and more. He has helped professional teams, Olympians and elite young athletes learn how to manage the intense pressure of competitive sports. He appears on both TV and radio and has sport psychology columns in 5 different newspapers and has been featured in The New York Times, Wall street Journal and the London Times. Golf Digest includes him in their list of top mental game gurus in America. For a consultation see below:

Williston Park Professional Center

2 Hillside Ave, Suite E. Williston Park NY 11596

(building parallel to E. Williston railroad station) drtomferraro.com drtferraro@aol.com

(516) 248-7189